Abstract C061: Real-World Outcomes of Immune Checkpoint Inhibitors and Emerging Immunotherapies in Molecularly Characterized NSCLC Treated in a Phase 1 Clinical Trial Unit
Year: 2025
Type: conference-abstract
Source: Molecular Cancer Therapeutics
Authors: Paula Rodríguez-Hernáez, Igor López, Manuel Pedregal, Bernard Doger, Victor Moreno, Alberto Ocana, Ester García-Lorenzo
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4415448625
Cites:
Cited by:
Related to: